Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)(GAP) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 |
| clinicaltrials |
| NCT05632939 | ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. | active not recruiting | Phase 1 / Phase 2 | 62 | AskGene Pharma, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05209074 | Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 16 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05669482 | Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer(RAMP205) | active not recruiting | Phase 1 / Phase 2 | 40 | Verastem, Inc.INDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06020885 | Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study. | active not recruiting | Phase 1 | 18 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05201352 | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine(TASKIN) | active not recruiting | Phase 1 / Phase 2 | 160 | Centre Georges Francois LeclercOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06532331 | A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 87 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT05083780 | Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer | active not recruiting | Phase 1 | 40 | Changhoon YooOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03795311 | Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)(FOLFIRINOX3) | active not recruiting | Phase 1 / Phase 2 | 32 | Centre Georges Francois LeclercOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04046445 | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer(KISIMA-01) | active not recruiting | Phase 1 | 96 | Amal TherapeuticsINDUSTRY | 4 | Jan 29, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03252808 | Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Patients with Unresectable Pancreatic Cancer. | active not recruiting | Phase 1 | 36 | Takara Bio Inc.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT06532344 | An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer | active not recruiting | Phase 1 | 32 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04511871 | A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors | active not recruiting | Phase 1 | 12 | Shanghai PerHum Therapeutics Co., Ltd.INDUSTRY | 1 | Oct 28, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06540261 | The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer | active not recruiting | Phase 1 | 65 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT06547385 | Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer | active not recruiting | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03544736 | Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC) | active not recruiting | Phase 1 / Phase 2 | 30 | Oslo University HospitalOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02496273 | Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer | active not recruiting | Phase 1 | 60 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 22, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 19, 2025source: clinicaltrials